Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,391 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Cancer Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 30, 2026, 10:38 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

NCT05287347
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Blood Specimen
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 30, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

NCT03077685
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
NanoPac®
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Fort Wayne, Indiana • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 30, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

NCT03714555
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Safety Laboratories, AE Assessment, Physical Exam, Concomitant Medication Review, Tumor Imaging, nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate, FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate, Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Diagnostic Test · Other · Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 105 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 30, 2026, 10:38 AM EDT
Not listed Phase 1 Interventional

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

NCT03703063
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, nab paclitaxel, Onivyde, Leucovorin, 5-fu
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 30, 2026, 10:38 AM EDT
Completed No phase listed Observational

Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection

NCT00584363
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 30, 2026, 10:38 AM EDT
Completed Not applicable Interventional

Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression

NCT01191814
View directory record Official record
Conditions
Obstructive Jaundice, Pancreatic Cancer
Interventions
Metal stent, Plastic stent
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
19 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 30, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

NCT03261947
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
Interventions
TAK-931
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Sarasota, Florida • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 30, 2026, 10:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 10:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NCT05451849
View directory record Official record
Conditions
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions
TC-510, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 10:38 AM EDT
Withdrawn Phase 2 Interventional

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

NCT06518538
View directory record Official record
Conditions
Pancreatic Cancer Stage IV
Interventions
CPI-613, modified Folfirinox
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 30, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

NCT02646748
View directory record Official record
Conditions
Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer)
Interventions
Pembrolizumab, itacitinib, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 30, 2026, 10:38 AM EDT
Completed Phase 2 Interventional

R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

NCT00005843
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 30, 2026, 10:38 AM EDT
Recruiting No phase listed Observational

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

NCT00899626
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Precancerous Condition
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2045
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 10:38 AM EDT
Withdrawn Phase 1 Interventional

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

NCT01741597
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Recurrent Pancreatic Cancer, Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Interventions
dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD
Procedure · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 30, 2026, 10:38 AM EDT
Not listed No phase listed Observational

Women At Risk: The High Risk Breast Cancer Program

NCT01034891
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2009 · Synced Oct 30, 2026, 10:38 AM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437
View directory record Official record
Conditions
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
Interventions
Niraparib
Drug
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
80
States / cities
Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 30, 2026, 10:38 AM EDT
Terminated Phase 1 Interventional

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

NCT05571839
View directory record Official record
Conditions
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Interventions
PF-08046049
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

NCT02487277
View directory record Official record
Conditions
Adenocarcinoma
Interventions
PEGPH20, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Andrew Ko
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 30, 2026, 10:38 AM EDT
Terminated Phase 1 Interventional

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

NCT02707328
View directory record Official record
Conditions
Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
Gemcitabine, nab-paclitaxel, CyberKnife
Drug · Radiation
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 30, 2026, 10:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128
View directory record Official record
Conditions
MTAP-deleted Solid Tumors
Interventions
BAY 3713372
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

NCT05074472
View directory record Official record
Conditions
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
Interventions
ZB131
Drug
Lead sponsor
ZielBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 30, 2026, 10:38 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

NCT01025570
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Bosutinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 30, 2026, 10:38 AM EDT